181 related articles for article (PubMed ID: 37846332)
21. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
[TBL] [Abstract][Full Text] [Related]
22. An overview of the irreversible electroporation for the treatment of liver metastases: When to use it.
Belfiore MP; De Chiara M; Reginelli A; Clemente A; Urraro F; Grassi R; Belfiore G; Cappabianca S
Front Oncol; 2022; 12():943176. PubMed ID: 36119531
[TBL] [Abstract][Full Text] [Related]
23. Tumor Ablation Enhancement by Combining Radiofrequency Ablation and Irreversible Electroporation: An In Vitro 3D Tumor Study.
Zhang B; Yang Y; Ding L; Moser MAJ; Zhang EM; Zhang W
Ann Biomed Eng; 2019 Mar; 47(3):694-705. PubMed ID: 30565007
[TBL] [Abstract][Full Text] [Related]
24. Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.
Nieuwenhuizen S; Dijkstra M; Puijk RS; Geboers B; Ruarus AH; Schouten EA; Nielsen K; de Vries JJJ; Bruynzeel AME; Scheffer HJ; van den Tol MP; Haasbeek CJA; Meijerink MR
Curr Oncol Rep; 2022 Jun; 24(6):793-808. PubMed ID: 35298796
[TBL] [Abstract][Full Text] [Related]
25. Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA).
Thamtorawat S; Patanawanitkul R; Rojwatcharapibarn S; Chaiyasoot W; Tongdee T; Yodying J; Sorotpinya S
Int J Hyperthermia; 2022; 39(1):751-757. PubMed ID: 35649727
[TBL] [Abstract][Full Text] [Related]
26. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer.
Paiella S; Salvia R; Girelli R; Frigerio I; Giardino A; D'Onofrio M; De Marchi G; Bassi C
Updates Surg; 2016 Sep; 68(3):307-311. PubMed ID: 27535401
[TBL] [Abstract][Full Text] [Related]
27. New Surgical Approach to Treat Fibroids and Solid Tumors - Thermal and Nonthermal Ablation.
Wong WF
Gynecol Minim Invasive Ther; 2023; 12(4):191-194. PubMed ID: 38034109
[TBL] [Abstract][Full Text] [Related]
28. Local ablation of pancreatic tumors: State of the art and future perspectives.
Granata V; Grassi R; Fusco R; Belli A; Palaia R; Carrafiello G; Miele V; Grassi R; Petrillo A; Izzo F
World J Gastroenterol; 2021 Jun; 27(23):3413-3428. PubMed ID: 34163121
[TBL] [Abstract][Full Text] [Related]
29. Alternative to surgery in early stage NSCLC-interventional radiologic approaches.
Lee KS; Pua BB
Transl Lung Cancer Res; 2013 Oct; 2(5):340-53. PubMed ID: 25806253
[TBL] [Abstract][Full Text] [Related]
30. Irreversible Electroporation For Liver Tumors: A Review Of Literature.
Tameez Ud Din A; Tameez-Ud-Din A; Chaudhary FMD; Chaudhary NA; Siddiqui KH
Cureus; 2019 Jun; 11(6):e4994. PubMed ID: 31497425
[TBL] [Abstract][Full Text] [Related]
31. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences?
Vroomen LGPH; Petre EN; Cornelis FH; Solomon SB; Srimathveeravalli G
Diagn Interv Imaging; 2017 Sep; 98(9):609-617. PubMed ID: 28869200
[TBL] [Abstract][Full Text] [Related]
32. Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study.
Zhang X; Zhang X; Ding X; Wang Z; Fan Y; Chen G; Hu X; Zheng J; Xue Z; He X; Zhang X; Wei Y; Zhang Z; Li J; Li J; Yang J; Xue X; Ma L; Xiao Y
Front Oncol; 2022; 12():945123. PubMed ID: 36249062
[TBL] [Abstract][Full Text] [Related]
33. Irreversible electroporation and the pancreas: What we know and where we are going?
Young SJ
World J Gastrointest Surg; 2015 Aug; 7(8):138-44. PubMed ID: 26328033
[TBL] [Abstract][Full Text] [Related]
34. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy.
Simmerman E; Chung J; Lawson A; Kruse E
J Surg Res; 2020 Feb; 246():260-268. PubMed ID: 31610354
[TBL] [Abstract][Full Text] [Related]
35. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE).
Kos B; Voigt P; Miklavcic D; Moche M
Radiol Oncol; 2015 Sep; 49(3):234-41. PubMed ID: 26401128
[TBL] [Abstract][Full Text] [Related]
36. Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma.
Eresen A; Yang J; Scotti A; Cai K; Yaghmai V; Zhang Z
Ann Transl Med; 2021 Jul; 9(13):1089. PubMed ID: 34423001
[TBL] [Abstract][Full Text] [Related]
37. Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors.
Verloh N; Jensch I; Lürken L; Haimerl M; Dollinger M; Renner P; Wiggermann P; Werner JM; Zeman F; Stroszczynski C; Beyer LP
Radiol Oncol; 2019 Mar; 53(1):116-122. PubMed ID: 30840591
[TBL] [Abstract][Full Text] [Related]
38. Niche Applications of Irreversible Electroporation.
Bhatia SS; Arya R; Narayanan G
Tech Vasc Interv Radiol; 2015 Sep; 18(3):170-5. PubMed ID: 26365547
[TBL] [Abstract][Full Text] [Related]
39. Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.
Wendler JJ; Pech M; Köllermann J; Friebe B; Siedentopf S; Blaschke S; Schindele D; Porsch M; Baumunk D; Jürgens J; Fischbach F; Ricke J; Schostak M; Böhm M; Liehr UB
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):466-476. PubMed ID: 28929209
[TBL] [Abstract][Full Text] [Related]
40. Irreversible electroporation induces CD8
Dai Z; Wang Z; Lei K; Liao J; Peng Z; Lin M; Liang P; Yu J; Peng S; Chen S; Kuang M
Cancer Lett; 2021 Apr; 503():1-10. PubMed ID: 33444692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
